本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
One of Europe's largest raises of its kind highlights Polus' leadership in the CLO and leveraged credit markets. LONDON, June 17, 2025 /PRNewswire/ -- Polus Capital Management ("Polus"), an investment management firm specialising in alternative credit strategies, is pleased to announce the initial close of its third CLO equity fund, Polus Loan Investments III ("PLI III"), with €425 million of commitments (approximately $485 million). The close represents one of Europe's largest CLO equity capital raises to date and underscores the firm's continued leadership in the global leveraged credit market. PLI III will invest in the equity tranches of Polus-managed CLOs – actively managed vehicles comprising diversified portfolios of broadly syndicated leveraged loans – as well as other CLO tranches and credit investments. Since launching its CLO management platform in 2006, Polus' Leveraged Credit team has raised approximately $12.7 billion globally including 21 new issues, 5 resets, and 6 refinancings.[1] The firm's CLO Equity Strategy has delivered consistent quarterly distributions for over a decade with an average net distribution yield to investors in the high teens.[2] Building on its success in Europe, Polus recently expanded its CLO management platform into the US, issuing its inaugural US CLO in 2024. The successful transition to a global CLO management platform reflects the firm's strong following and reputation among institutional investors globally. Since 2014, Polus has raised more than $1 billion in committed capital to invest in Polus-managed CLOs and other credit investments across Europe and the US.1 PLI III marks the firm's largest CLO equity capital raise to date, providing significant runway for future CLO issuance while maintaining a focus on delivering strong risk-adjusted returns for investors.[3] Polus' Leveraged Credit team brings nearly two decades of structuring, investment, and trading experience within CLOs. The team has invested approximately $21 billion across more than 2,100 broadly syndicated leveraged loans since inception and is currently invested in more than 500 issuers across Europe and the US.[4] Nicholas Chalmers, Chief Executive Officer at Polus Capital Management, said: "We are very proud of the performance of our Leveraged Credit team and CLO management platform. The strong initial close for PLI III reflects investors' confidence in our investment process and in the consistency of our track record. As one of Europe's largest CLO equity closes to date, this milestone reinforces our role as a trusted long-term partner to institutional investors seeking high yield and diversification through alternative credit strategies." Notes for Editors About Polus Capital Management Polus Capital Management ("Polus") is an investment management firm specialising in alternative credit strategies. Polus has approximately $13 billion in assets under management1 and invests across the capital structure and liquidity spectrum, focusing on three complementary investment verticals: Leveraged Credit, Special Situations and Structured Credit. Polus has offices in London and New York. Media Enquiries Greenbrook – Rob White / Ksenia Galouchko polus@greenbrookadvisory.com +44 207 952 2000 [1] Assets Under Management and Advice: AUM figures include assets under management and advice of Polus group companies as well as CLO vehicles managed by Cairn Loan Investments LLP ("CLI I") and Cairn Loan Investments II LLP ("CLI II"). CLI I and CLI II are not affiliates of Polus nor of each other, but Polus established them as independent CLO managers and provides them with key support services ("Services"). AUM figures are estimated as at 31 May 2025 and include the initial close commitments to PLI III and other uncalled commitments. AUM figures are subject to rounding and FX fluctuations. Metrics related to the past and present investment activity of the Leveraged Credit team includes leveraged loans and high yield bonds managed by Polus in CLO vehicles, single investor solutions and commingled funds, as well as leveraged loans and high yield bonds managed in CLO vehicles by CLI I and CLI II. [2] Performance Notes: Past performance is not necessarily indicative of future performance and future returns are not guaranteed. Securities and derivatives trading are speculative and involve substantial risk of loss. Performance may increase or decrease as a result of FX fluctuations. "CLO Equity Strategy" refers to the strategy Polus carried out through CLI I and/or CLI II. An investment in CLI I and/or CLI II provides investors with exposure primarily to the equity tranche of Polus-managed CLOs plus a revenue share in the collateral management fees earned by CLI I and CLI II for managing the CLOs. "Polus-managed CLOs" refers to CLOs managed or serviced by Polus' Leveraged Credit team, including CLOs managed by CLI I or CLI II, which share or have shared a common investment team with Polus through the provision of Services. Neither CLI I nor CLI II charged a management fee or incentive fee to investors in CLI I or CLI II. Accordingly, net returns for an investment in CLI I and CLI II assume no management fee or incentive fee but do include expenses related to the operating cost of CLI I and CLI II, respectively. Further details of expenses are available upon request. The return to investors in CLI I and CLI II comprises primarily the return from investments in the equity tranche of Polus-managed CLOs (which is, by definition, net of management fees and, where applicable, incentive fees applied at the level of the CLO), but also includes a revenue share in the management fees earned by CLI I and CLI II for managing the CLOs. Performance figures have been calculated by Polus and have not been independently verified. The composite aggregate net performance statistics for the CLO Equity Strategy (e.g. net distribution yield) are based on actual performance data of CLI I and CLI II as if they had been one continuous vehicle, utilising the weighted average of the two vehicles based on their respective sizes during the period for which the vehicles overlap, over the period from 2014 to present. The actual performance of an investment in CLI I or CLI II will vary from the composite performance and no representation is made that any vehicle or investor will or is likely to achieve the results shown. Performance figures have been calculated by Polus using the official internal records and investor reporting data and have not been independently verified. [3] PLI III: There can be no assurance that PLI III will achieve results comparable to any past results, that the returns generated by PLI III will equal or exceed those of CLI I, CLI II or any other funds or accounts advised, sponsored or managed by Polus or that PLI III will be able to implement its investment strategy or achieve its investment objectives. Prospective investors should review PLI III's offering documents for additional important information regarding risks of investing and potential conflicts of interest associated with PLI III. PLI III will only accept investments from institutional investors (i.e. accredited investors in the US or other 'professional investors'). [4] Team: Certain members of the Leveraged Credit Team may not have performed or provided services to Polus, CLI I or CLI II and may not necessarily have held such positions or been employed by Polus, in each case as applicable, for the entire term of the team's operating history. Similarly, such persons may not necessarily continue to hold such positions with or provide services to Polus, CLI I or CLI II (as applicable) in the future.
SCHÖPPINGEN, Germany, June 17, 2025 /PRNewswire/ -- Today, Shopware introduced Agentic Commerce and new AI-driven solutions shaping the future of e-commerce, placing a stronger focus on AI while furthering their expansion into B2B. The keynote emphasized why—when faced with challenges and uncertainties—merchants require a reliable technology partner to meet the demands of today and plan for tomorrow. Shopware AISebastian Hamann, Co CEO, introduced Shopware AI based on human shopping behavior: "On the one hand, there are rational purchasing decisions, based on need and fact-based analysis. On the other, emotional decisions, driven by feelings, impulses, and subconscious factors. The future of digital commerce begins where AI meets real merchant needs." Shopware AI combines both, encompassing all AI-powered features, from image and text editing to tools that enhance the shopping experience and the new chat-based Copilot. This assistant supports merchants managing routine tasks, ultimately saving time for customer service or strategic work. The AI-powered Image Editor, a new function, allows merchants to easily place products into scenes with realistic shadows and reflections, resulting in high-quality campaign images which are automatically uploaded into the Shopware Media Manager and ready to be utilized. Agentic CommerceAgentic Commerce enables intelligent agents to handle decisions, shortening the sales cycle from quote to purchase. Shopware AI aims to increase revenue, lower integration costs, create differentiated shopping experiences, and drive monetization. The launch of the Copilot is the first step, with further features like AI Agents to follow soon. Shopware also announced the "Agentic Commerce Alliance," bringing together AI-first companies to establish common standards and share practical AI patterns. Some well-known partners are already on board. B2B Components Over 60% of Shopware's merchants operate in B2B or hybrid models- including companies like Toyota and Ritter Sport. "Complex Commerce is becoming reality—and Shopware powers it," Hamann said. New 'B2B Components' support growth at every stage, including: Organization Units: Define parameters like shipping addresses or payment methods to reduce manual errors. Advanced Product Catalogs: Create custom product catalogs for faster quote processes. The Community HubThe open-source model remains a strategic advantage which is why Shopware introduced the Community Hub to strengthen collaboration: Knowledge sharing: Gamified content helps users learn faster. Collaboration: Developer productivity has tripled. Networking: Connects members across all levels. Further information, featured updates, and the keynote can be found on the Special Event page.
BOSTON, June 17, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, has launched OPUS Link Lab (OLL)—a revolutionary, no-cost design environment created to supercharge the creation and commercialization of multienterprise solutions across the life sciences ecosystem. Sparked by significant customer and partner demand, OPUS Link Lab empowers solution developers, IT leaders, and technologists with a free, secure, and always-on, no-code design environment packed with TraceLink's most advanced orchestration capabilities. Users can immediately begin designing, testing, and demoing transformative supply chain solutions leveraging: B2N (Business-to-Network) Integrate-Once™ - With OPUS's B2N Integrate-Once™ model, customers and trading partners integrate a single time and instantly link to any partner on the network. No more rebuilding the same integration for every relationship; just link in and scale through many OPUS solutions. Multienterprise Information Network Tower (MINT) - Provides end-to-end, real-time transaction visibility and intelligence across the life sciences and healthcare supply chain, enabling companies and their trading partners to make faster, data-driven decisions and proactively source real-time, end-to-end commercial and supply chain information for advancing GenAI strategies. Process Orchestration for Empowered Teams (POET) - Streamlines and automates cross-functional, person-to-person business processes, empowering teams with real-time collaboration, transparency, and control to drive faster, more accurate outcomes. OPUS Solution Environment (OSE) – A breakthrough no-code toolset enabling users to rapidly assemble enterprise and multienterprise solutions with drag-and-drop ease. OPUS Reports and Dashboards (ORD) – A robust, no-code reporting and analytics suite that allows business users to create real-time visualizations and performance dashboards of end-to-end supply chain information, enabling leaders to gain instant visibility into supply chain KPIs for faster decision-making and data-driven execution. Link Actions and Transforms - Rapidly build event-driven links between OPUS solutions and common enterprise systems using Link Actions and apply dynamic, no-code transforms to standardize and route data across systems. This combination enables fast, flexible integration with enterprise applications without the time and cost of custom development. "OPUS Link Lab accelerates digital transformation by giving innovators everything they need to create, test, and deploy supply chain solutions without barriers," said Shabbir Dahod, President and CEO of TraceLink. "With OLL and our no-code OPUS Solution Environment, anyone—from system integrators to in-house IT teams—can rapidly turn ideas into multienterprise-grade solutions that improve agility, resilience, and business performance with trading partners." With OPUS Link Lab, users can rapidly and affordably digitalize processes and craft tailored solutions to solve real-world, multienterprise supply chain challenges, including: Commercial and Channel Management. Order-to-cash/procure-to-pay optimization, channel inventory control and optimization, demand sensing, financial reconciliation and claims adjudication. Supply Chain Planning. Forecast and scenario planning, production planning and scheduling, material and resourcing planning, S&OP alignment. External Manufacturing and Manufacturing Execution. Forecast and order planning, production tracking, material supply coordination, tech transfer collaboration, resource planning, and OEE monitoring. Quality Management. Continuous quality improvement, batch record review collaboration, issue and exception resolution, compliant and adverse event management. Procurement and Supplier Management. Agreement and licensing coordination, qualification and performance assessment, sustainability scorecarding. Regulatory Affairs and Compliance. Regulatory submission and tracking, label and artwork management, risk and impact assessment, and inspection and audit management. OPUS Link Lab also includes access to curated training paths, hands-on documentation, pre-built solution templates, and community forums led by TraceLink experts—all designed to fast-track network ecosystem success. Whether you're building your first digital orchestration flow or scaling multienterprise solutions across global networks, OPUS Link Lab makes it possible—today. Learn more about OPUS Link Lab and register for access here. About TraceLinkTraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once™ network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of healthcare products, ensuring that every patient gets the medicines they need when needed, safely and securely.
New I/O solution gives manufacturers greater design freedom to build smarter, more adaptable machines MILWAUKEE, Wis., June 17, 2025 /PRNewswire/ -- Rockwell Automation, Inc. (NYSE: ROK), the world's largest company dedicated to industrial automation and digital transformation, today announced the release of PointMax™ I/O, a flexible remote input/output (I/O) system designed to help manufacturers tackle the growing complexity of modern industrial operations. Rockwell Automation introduces PointMax I/O to empower flexible industrial system design and reduce operational complexity As manufacturing environments become increasingly dynamic and interconnected, the ability to quickly adapt system architectures is more important than ever. Traditional I/O systems, which rely on extensive wiring and large control cabinets, are becoming harder to scale and maintain as production demands grow and equipment footprints shrink. To keep pace, manufacturers need flexible and efficient solutions that allow for design flexibility without adding unnecessary complexity. PointMax I/O was built to address the real-world constraints manufacturers face on the plant floor. Its modular design supports scalable and easily reconfigurable I/O deployments—freeing engineers from the constraints of rigid, centralized control systems. For both new machine builds and existing equipment, PointMax I/O delivers the flexibility today's fast-paced manufacturing operations demand. "Customers are looking for smarter, more adaptable solutions that remove friction from system design and maintenance," says Karthikeyan Mahalingam, product manager at Rockwell Automation. "PointMax I/O delivers on that need by offering a simpler way to connect devices, gather insights and keep operations running smoothly. It's about giving manufacturers more control and fewer constraints as they scale." With maximum design freedom and seamless integration with Logix 5000 controllers, PointMax I/O is well suited for high-performance environments that need reliability and real-time communication. It's also built to withstand tough industrial conditions, making it a strong fit for a wide range of applications. The system is being showcased for the first time this week at ROKLive EMEA in Rome, where attendees can explore the technology through live demonstrations, hands-on labs and technical sessions. PointMax I/O is expected to be available for order in Q3 2025. To learn more, visit Rockwell's website. About Rockwell Automation Rockwell Automation, Inc. (NYSE: ROK) is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 27,000 problem solvers dedicated to our customers in more than 100 countries as of fiscal year end 2024. To learn more about how we are bringing the Connected Enterprise® to life across industrial enterprises, visit www.rockwellautomation.com.
SKY-0515 is an oral small molecule designed to reduce the production of both huntingtin (HTT) and PMS1 proteins—two key drivers of HD pathology Initiation of the FALCON-HD trial follows promising Phase 1 results demonstrating up to 72% reduction in HTT mRNA in healthy volunteers The SKY-0515 Phase 1 trial in patients with Huntington's disease reached full enrollment ahead of schedule BOSTON, June 18, 2025 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced that the first patient has been dosed in its Phase 2/3 FALCON-HD trial evaluating SKY-0515, an investigational oral RNA splicing modulator for the treatment of Huntington's disease (HD). SKY-0515 is designed to reduce the production of both HTT and PMS1 proteins—two key drivers of HD pathology. In a Phase 1 study in healthy volunteers, SKY-0515 demonstrated dose-dependent HTT mRNA reduction, achieving an average of 72% lowering at the highest dose tested. The compound was generally well tolerated across all doses. Additionally, the Company's Phase 1 trial in HD patients, which began in January 2025, completed enrollment ahead of schedule in March 2025. "Dosing the first patient in our FALCON-HD trial marks a significant milestone in our mission to develop a disease-modifying therapy for Huntington's patients," said Bill Haney, Founder and Chief Executive Officer of Skyhawk Therapeutics. "Building on our compelling Phase 1 data, we are eager to assess SKY-0515's potential to make a meaningful difference in the lives of patients affected by this devastating condition." FALCON-HD is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in participants with Stage 2 and early Stage 3 HD. The trial includes multiple sites across Australia and New Zealand. The initial dosing took place at Flinders Medical Centre in Adelaide, Australia. "We are pleased to participate in this important clinical trial and to have dosed the first patient here at Flinders," said Dr. Karyn Boundy, FRACP, Neurologist, Principal Investigator at Flinders Medical Centre. "Given the lack of approved disease-modifying treatments for Huntington's disease, we are hopeful that SKY-0515 could offer a new therapeutic option for patients." "As Skyhawk kicks off their Phase 2/3 FALCON-HD trial in Australia and New Zealand, the international Huntington's community looks forward to expansion worldwide," said Ed Wild, professor of neurology at the University College London. "SKY-0515's unique ability to reduce both HTT and PMS1 could meaningfully enhance therapeutic impact beyond that of lowering HTT alone." About the FALCON-HD TrialFALCON-HD (NCT06873334) is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in participants with Stage 2 and early Stage 3 HD. The trial plans to enroll 120 subjects across 10 sites in Australia and New Zealand. Eligible patients will receive a once-daily oral dose of SKY-0515 at one of three dose levels, or placebo, for a treatment period of at least 12 months. The trial aims to assess the potential of SKY-0515 to modulate RNA splicing and reduce the production of huntingtin (HTT) and PMS1 proteins, which are implicated in the pathology of Huntington's disease. Additional information about FALCON-HD, including participating sites and eligibility criteria, can be found at ClinicalTrials.gov and www.FALCON-HD.com. About SKY-0515SKY-0515 is an orally administered small molecule RNA splicing modulator developed through Skyhawk's proprietary platform. It is designed to reduce production of both huntingtin (HTT) and PMS1 proteins, two key contributors to Huntington's disease. SKY-0515 has shown robust, dose-dependent HTT mRNA reduction—up to 72%—in healthy volunteer studies, with favorable safety and tolerability. SKY-0515 is currently being evaluated in a Phase 2/3 clinical trial. About Skyhawk TherapeuticsSkyhawk Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapies designed to modulate critical RNA targets and revolutionize patient treatment for some of the world's most intractable diseases. Skyhawk's discovery expertise is rooted in its proprietary drug discovery platform, which assesses, identifies, and tests RNA splicing targets and small molecules across a broad range of therapeutic areas and disease states. Skyhawk has built collaborations with multiple pharma partners that leverage Skyhawk's novel platform across disease areas including neurodegenerative disease, autoimmune disease, and oncology. For more information visit www.skyhawktx.com. Skyhawk ContactsKyle Dow, VP Corporate Developmentkyle.dow@skyhawktx.com Logo - https://mma.prnasia.com/media2/710814/Skyhawk_Therapeutics_Logo.jpg?p=medium600
SHANGHAI, June 17, 2025 /PRNewswire/ -- From March 31 to April 3, Hotel & Shop Plus 2025 has achieved a successful conclusion in SNIEC, Shanghai. As China's leading trade show, it has been devoted to hospitality and commercial space for more than 30 years. This event aims to be built as one-stop sourcing platform for the construction and operation of hotels and commercial space. A Global Hospitality Marketplace Spanning 210,000 sqm, the exhibition attracted 1,482 exhibitors and 134,953 professional visitors, covering the entire supply chain from building materials, smart hotel, lighting & intelligent controls, office space, hotel supplies, cleaning and maintenance. Notably, this year's exhibition saw a record-high number of international attendees on-site with 8,651 overseas visitors from 124 countries and regions—led by Russia, South Korea, Thailand, Singapore, Malaysia, Japan, the Philippines, India, Australia, and Vietnam. Their presence not only added a strong international atmosphere to the exhibition but also further enhanced its global influence. High-Impact Forums & Elite Speakers Over 90 high-end forums and professional events were held concurrently during the exhibition, including the 'Ecology & Coexistence' China International Building & Interior Design Forum, featuring Joris Angevaare, Partner of HBA; Mark Eacott, Founder of Ennismore; Eric W. Tsay, Founder of Studio STAY; and Shanshan Qi, Founder of STUDIO QI ARCHITECTS. They explored cases of sustainable design applied in urban renewal, resort lifestyles, eco-integrated construction, and other fields. Additionally, at the China International Lighting Design Forum, Martin Klaasen, Managing Partner of Nulty; Emmanuel Clair, CEO of Light Cibles; Uno Lai, Founder of ULDA; Wanjun Bai, General Manager of Bamboo Lighting Design; and Sony Wang, President of BPI, shared their unique insights on lighting. The session attracted over 300 industry experts and attendees for lively on-site interaction and discussion. Other highlights included the LIV Hotel Design Summit, Hotel Mockup Room Show, Hotel Uniform Show, and the 2025 Hotel Procurement Forum, among other exciting events. Global Connections & Major Deals The fair facilitated 500+ matchmaking sessions, connecting 150+ exhibitors with 100+ global buyers from France, Canada, Brazil, and beyond, securing exciting cooperative projects and large orders, leaving both exhibitors and buyers highly satisfied with the fruitful outcomes. Mark Your Calendars: 2025 Hotel & Shop Plus Shenzhen will take place from 16–18 December 2025 at Shenzhen World Exhibition & Convention Centre. 2026 Hotel & Shop Plus Shanghai will take place from March 31–April 3, 2026, at SNIEC. Stay tuned for further event news! Explore more, visit our website： https://www.expohsp.com/?lang=en
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
